Intermittent Theta-Burst Stimulation (iTBS) Improves Motor Coordination and Modulates Neuroinflammation and Autophagy in SCA3/MJD Mice

Spinocerebellar ataxia type 3 (SCA3), also called Machado-Joseph disease, is an inherited brain disorder in which a misfolded protein called ataxin-3 builds up inside neurons of the cerebellum, progressively destroying balance and coordination. There is currently no disease-modifying treatment. Researchers tested whether a non-invasive brain stimulation technique — intermittent theta-burst stimulation (iTBS), a patterned form of transcranial magnetic stimulation applied over the skull — could slow this damage in a mouse model of the disease. Mice receiving iTBS over two weeks showed markedly better motor performance: they stayed on a rotating rod longer and walked with more symmetrical, regular gait patterns. At the tissue level, iTBS reduced the toxic ataxin-3 protein load and the clumped protein deposits (ubiquitin-positive inclusions) that choke neurons. Mechanistically, iTBS appeared to shift the brain's immune cells (microglia) toward an anti-inflammatory state and activated autophagy — the cell's internal recycling machinery that degrades misfolded proteins — as shown by increases in two key autophagy markers, Beclin-1 and LC3B. A comparison stimulation pattern called continuous theta-burst stimulation (cTBS) produced only partial and weaker effects, suggesting that the specific timing of magnetic pulses matters. The findings position iTBS as a candidate non-pharmacological intervention for polyglutamine neurodegenerative diseases, though translation to humans will require substantial further work.

• iTBS significantly reduced rotarod falls versus both sham (P < 0.001) and cTBS (P < 0.05) groups, indicating superior improvement in cerebellar motor coordination with the intermittent paradigm.
• iTBS lowered cerebellar ataxin-3 protein expression and ubiquitin-positive neuronal inclusions compared with sham (both P < 0.01) and cTBS (P < 0.01 and P < 0.05 respectively), suggesting reduced pathological protein burden.
• Only iTBS — not cTBS — increased CD206-positive (M2-like anti-inflammatory) microglial cells (vs. sham P < 0.05) and downregulated pro-inflammatory cytokines, while both paradigms raised total Iba-1-positive microglial counts.
• iTBS activated autophagy flux, elevating Beclin-1 (vs. sham P < 0.05) and LC3B expression (vs. sham P < 0.0001; vs. cTBS P < 0.001), consistent with enhanced autophagic clearance of misfolded ataxin-3.
• CatWalk gait analysis showed iTBS improved both gait symmetry (vs. sham P < 0.05) and regularity index (vs. sham P < 0.01; vs. cTBS P < 0.01), providing multi-dimensional functional corroboration beyond the rotarod alone.

This was a randomised controlled animal study using 30 SCA3/MJD transgenic mice aged 14 weeks, divided equally into sham, cTBS, and iTBS groups (n = 10 per group). Cerebellar TMS was delivered at 30% of maximum stimulator output, 600 pulses per session, once daily, five days per week for two weeks. Motor outcome was assessed by rotarod test and CatWalk automated gait analysis. Cerebellar tissue was examined post-intervention for ataxin-3 and ubiquitin immunohistochemistry, microglial markers (Iba-1, CD206), a multi-cytokine array, and Western blotting for Beclin-1 and LC3B.

The study used only male or mixed-sex transgenic mice at a single disease stage (14 weeks), so effects across the disease trajectory, in females, or in other SCA subtypes remain unknown. The two-week intervention window is short relative to the chronic progressive course of SCA3, and no washout or long-term follow-up data are reported, leaving durability of benefit unclear. Autophagy activation is inferred from two protein markers (Beclin-1 and LC3B) without flux assays (e.g., lysosomal inhibitor experiments) or upstream pathway dissection (mTOR, AMPK), so the precise signalling cascade linking electromagnetic stimulation to autophagic induction is unresolved. Direct translation to humans is also uncertain because human cerebellar anatomy and skull geometry differ substantially from mice, and optimal human iTBS parameters for deep cerebellar targets are not established.

This study extends [§81], which identifies neuroinflammation and autophagy modulation as converging therapeutic axes in polyglutamine and amyloid-driven neurodegeneration, by demonstrating that a physical, non-pharmacological stimulus (iTBS) can engage both pathways simultaneously in a cerebellar disease context. It parallels [§130], which shows that intermittent metabolic stressors (fasting) activate autophagy as a neuroprotective mechanism, suggesting that periodic, pulsatile stimuli — whether dietary or electromagnetic — may share a common capacity to upregulate cellular recycling. The autophagy-clearance findings also resonate with [§37], where CHCHD2/CHCHD10 proteins facilitate autophagic disposal of protein aggregates via selective autophagy receptors, reinforcing the emerging principle that enhancing aggregate clearance flux is a viable strategy in proteinopathies. Relative to [§38], which maps the mechanistic landscape of mammalian lysophagy and selective autophagy, the current work does not specify whether iTBS-driven clearance of ataxin-3 operates through canonical macroautophagy or a selective subtype, representing a key gap for future mechanistic studies.

• FOXO transcription factors in Alzheimer's Disease: balancing neuroprotection and neuronal degeneration
  Directly parallel disease context — both articles treat neuroinflammation and autophagy as dual therapeutic targets in neurodegenerative disease, allowing readers to compare pharmacological (FOXO-pathway) versus physical (iTBS) strategies for engaging these mechanisms.
• Regulatory impact of intermittent fasting on autophagy in high fat diet induced structural and cognitive brain deteriorations in rats
  Both use a periodic, pulsatile intervention (iTBS vs. intermittent fasting) to activate autophagy in a neurodegeneration model, making this a useful comparison for understanding whether the autophagy benefit is stimulus-specific or a general response to intermittent biological challenge.
• CHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs
  CHCHD2/CHCHD10-mediated autophagic clearance of protein aggregates via GABARAP receptors offers a molecular-level mechanistic counterpoint: comparing it with iTBS data helps readers assess whether the aggregate clearance seen here likely involves selective autophagy receptors or bulk autophagy induction.
• Mammalian Lysophagy: mechanisms and pathophysiological implications
  This review of mammalian lysophagy mechanisms provides the conceptual framework needed to interrogate whether iTBS-enhanced clearance of ataxin-3 inclusions proceeds through canonical autophagosome-lysosome fusion or a selective lysosomal repair pathway — a distinction the current study leaves open.